Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the…
Raleigh-Durham, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, today announced it has been awarded an…